Toward a Combination of Biomarkers for Molecular Characterization of Multiple Sclerosis
Abstract
:1. Introduction
2. Results
2.1. EAE Molecular Signature in the Spinal Cord and Brain
2.1.1. Inflammation-Related Genes
2.1.2. BBB Disruption-Related Genes
2.1.3. Astrocyte-Related Genes
2.1.4. Oligodendrocyte and Neuronal Damage-Related Genes
2.1.5. Microglia Activation-Related Genes
2.1.6. Repair Mechanisms Related Genes
2.2. EAE Molecular Signature in Cells Type
2.2.1. Oligodendrocyte-Specific Changes in Gene Expression
2.2.2. Specific Gene Expression Changes in CNS Phagocytic Cells
3. Discussion
4. Materials and Methods
4.1. Animals
4.2. Tissue Isolation
4.3. Cell Separation
4.4. RNA Extraction and Quantitative Real-Time PCR
4.5. Statistical Analysis
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Weiner, H.L. Multiple Sclerosis Is an Inflammatory T-Cell–Mediated Autoimmune Disease. Arch. Neurol. 2004, 61, 1613–1615. [Google Scholar] [CrossRef]
- Ziemssen, T.; Akgün, K.; Brück, W. Molecular biomarkers in multiple sclerosis. J. Neuroinflamm. 2019, 16, 272. [Google Scholar] [CrossRef] [Green Version]
- Gafson, A.; Craner, M.J.; Matthews, P.M. Personalised medicine for multiple sclerosis care. Mult. Scler. J. 2016, 23, 362–369. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lucchinetti, C.; Brück, W.; Parisi, J.; Scheithauer, B.; Rodriguez, M.; Lassmann, H. Heterogeneity of Multiple Sclerosis Lesions: Implications for the Pathogenesis of Demyelination. Ann. Neurol. 2000, 47, 707–717. [Google Scholar] [CrossRef]
- Constantinescu, C.S.; Farooqi, N.; O’Brien, K.; Gran, B. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). J. Cereb. Blood Flow Metab. 2011, 164, 1079–1106. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Steinman, L.; Zamvil, S.S. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol. 2005, 26, 565–571. [Google Scholar] [CrossRef]
- Gold, R.; Linington, C.; Lassmann, H. Understanding Pathogenesis and Therapy of Multiple Sclerosis via Animal Models: 70 Years of Merits and Culprits in Experimental Autoimmune Encephalomyelitis Research. Brain 2006, 129, 1953–1971. [Google Scholar] [CrossRef] [Green Version]
- Tuohy, V.K.; Sobel, R.A.; Lees, M.B. Myelin Proteolipid Protein-Induced Experimental Allergic Encephalomyelitis. Variations of Disease Expression in Different Strains of Mice. J. Immunol. 1988, 140, 1868–1873. [Google Scholar]
- Birmpili, D.; Charmarke Askar, I.; Bigaut, K.; Bagnard, D. The Translatability of Multiple Sclerosis Animal Models for Biomarkers Discovery and Their Clinical Use. Int. J. Mol. Sci. 2022, 23, 11532. [Google Scholar] [CrossRef]
- Balasa, R.; Barcutean, L.; Mosora, O.; Manu, D. Reviewing the Significance of Blood–Brain Barrier Disruption in Multiple Sclerosis Pathology and Treatment. Int. J. Mol. Sci. 2021, 22, 8370. [Google Scholar] [CrossRef]
- Behl, T.; Kaur, G.; Sehgal, A.; Bhardwaj, S.; Singh, S.; Buhas, C.; Judea-Pusta, C.; Uivarosan, D.; Munteanu, M.A.; Bungau, A.S. Multifaceted Role of Matrix Metalloproteinases in Neurodegenerative Diseases: Pathophysiological and Therapeutic Perspectives. Int. J. Mol. Sci. 2021, 22, 1413. [Google Scholar] [CrossRef] [PubMed]
- Bennett, M.L.; Bennett, F.C.; Liddelow, S.A.; Ajami, B.; Zamanian, J.L.; Fernhoff, N.B.; Mulinyawe, S.B.; Bohlen, C.J.; Adil, A.; Tucker, A.; et al. New tools for studying microglia in the mouse and human CNS. Proc. Natl. Acad. Sci. USA 2016, 113, E1738–E1746. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Washington, R.A.; Becher, B.; Balabanov, R.; Antel, J.; Dore-Duffy, P. Expression of the Activation Marker Urokinase Plasminogen-Activator Receptor in Cultured Human Central Nervous System Microglia. J. Neurosci. Res. 1996, 45, 392–399. [Google Scholar] [CrossRef]
- Muszyński, P.; Groblewska, M.; Kulczyńska-Przybik, A.; Kułakowska, A.; Mroczko, B. YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer’s Disease. Curr. Neuropharmacol. 2017, 15, 906–917. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Manicone, A.M.; McGuire, J.K. Matrix Metalloproteinases as Modulators of Inflammation. Semin. Cell Dev. Biol. 2008, 19, 34–41. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cubas-Núñez, L.; Gil-Perotín, S.; Castillo-Villalba, J.; López, V.; Tarazona, L.S.; Gasqué-Rubio, R.; Carratalá-Boscá, S.; Alcalá-Vicente, C.; Pérez-Miralles, F.; Lassmann, H.; et al. Potential Role of CHI3L1+ Astrocytes in Progression in MS. Neurol.—Neuroimmunol. Neuroinflamm. 2021, 8, e972. [Google Scholar] [CrossRef]
- Hinsinger, G.; Galéotti, N.; Nabholz, N.; Urbach, S.; Rigau, V.; Demattei, C.; Lehmann, S.; Camu, W.; Labauge, P.; Castelnovo, G.; et al. Chitinase 3-like Proteins as Diagnostic and Prognostic Biomarkers of Multiple Sclerosis. Mult. Scler. 2015, 21, 1251–1261. [Google Scholar] [CrossRef]
- Cantó, E.; Reverter, F.; Morcillo-Suárez, C.; Matesanz, F.; Fernández, O.; Izquierdo, G.; Vandenbroeck, K.; Rodríguez-Antigüedad, A.; Urcelay, E.; Arroyo, R.; et al. Chitinase 3-like 1 Plasma Levels Are Increased in Patients with Progressive Forms of Multiple Sclerosis. Mult. Scler. 2012, 18, 983–990. [Google Scholar] [CrossRef]
- Starossom, S.C.; Campo Garcia, J.; Woelfle, T.; Romero-Suarez, S.; Olah, M.; Watanabe, F.; Cao, L.; Yeste, A.; Tukker, J.J.; Quintana, F.J.; et al. Chi3l3 Induces Oligodendrogenesis in an Experimental Model of Autoimmune Neuroinflammation. Nat. Commun. 2019, 10, 217. [Google Scholar] [CrossRef] [Green Version]
- Bonneh-Barkay, D.; Wang, G.; LaFramboise, W.A.; Wiley, C.A.; Bissel, S.J. Exacerbation of Experimental Autoimmune Encephalomyelitis in the Absence of Breast Regression Protein 39/Chitinase 3-Like 1. J. Neuropathol. Exp. Neurol. 2012, 71, 948–958. [Google Scholar] [CrossRef] [Green Version]
- van der Poel, M.; Ulas, T.; Mizee, M.R.; Hsiao, C.-C.; Miedema, S.S.; Schuurman, K.G.; Helder, B.; Tas, S.W.; Schultze, J.L.; Hamann, J.; et al. Transcriptional Profiling of Human Microglia Reveals Grey–White Matter Heterogeneity and Multiple Sclerosis-Associated Changes. Nat. Commun. 2019, 10, 1139. [Google Scholar] [CrossRef] [PubMed]
- Masuda, T.; Sankowski, R.; Staszewski, O.; Böttcher, C.; Amann, L.; Scheiwe, C.; Nessler, S.; Kunz, P.; van Loo, G.; Coenen, V.A.; et al. Spatial and Temporal Heterogeneity of Mouse and Human Microglia at Single-Cell Resolution. Nature 2019, 566, 388–392. [Google Scholar] [CrossRef] [PubMed]
- Denhardt, D.T.; Noda, M.; O’Regan, A.W.; Pavlin, D.; Berman, J.S. Osteopontin as a Means to Cope with Environmental Insults: Regulation of Inflammation, Tissue Remodeling, and Cell Survival. J. Clin. Investig. 2001, 107, 1055–1061. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chabas, D.; Baranzini, S.E.; Mitchell, D.; Bernard, C.C.A.; Rittling, S.R.; Denhardt, D.T.; Sobel, R.A.; Lock, C.; Karpuj, M.; Pedotti, R.; et al. The Influence of the Proinflammatory Cytokine, Osteopontin, on Autoimmune Demyelinating Disease. Science 2001, 294, 1731–1735. [Google Scholar] [CrossRef]
- Selvaraju, R.; Bernasconi, L.; Losberger, C.; Graber, P.; Kadi, L.; Avellana-Adalid, V.; Picard-Riera, N.; Baron Van Evercooren, A.; Cirillo, R.; Kosco-Vilbois, M.; et al. Osteopontin Is Upregulated during in Vivo Demyelination and Remyelination and Enhances Myelin Formation in Vitro. Mol. Cell. Neurosci. 2004, 25, 707–721. [Google Scholar] [CrossRef]
- Wang, J.-B.; Zhang, Z.; Li, J.-N.; Yang, T.; Du, S.; Cao, R.-J.; Cui, S.-S. SPP1 Promotes Schwann Cell Proliferation and Survival through PKCα by Binding with CD44 and Avβ3 after Peripheral Nerve Injury. Cell Biosci. 2020, 10, 98. [Google Scholar] [CrossRef]
- Bohnert, S.; Seiffert, A.; Trella, S.; Bohnert, M.; Distel, L.; Ondruschka, B.; Monoranu, C.-M. TMEM119 as a Specific Marker of Microglia Reaction in Traumatic Brain Injury in Postmortem Examination. Int. J. Legal Med. 2020, 134, 2167–2176. [Google Scholar] [CrossRef]
- Karperien, A.; Ahammer, H.; Jelinek, H.F. Quantitating the Subtleties of Microglial Morphology with Fractal Analysis. Front. Cell. Neurosci. 2013, 7, 3. [Google Scholar] [CrossRef] [Green Version]
- Kuntzel, T.; Bagnard, D. Manipulating Macrophage/Microglia Polarization to Treat Glioblastoma or Multiple Sclerosis. Pharmaceutics 2022, 14, 344. [Google Scholar] [CrossRef]
- Tzartos, J.S.; Friese, M.A.; Craner, M.J.; Palace, J.; Newcombe, J.; Esiri, M.M.; Fugger, L. Interleukin-17 Production in Central Nervous System-Infiltrating T Cells and Glial Cells Is Associated with Active Disease in Multiple Sclerosis. Am. J. Pathol. 2008, 172, 146–155. [Google Scholar] [CrossRef] [Green Version]
- Moyon, S.; Dubessy, A.L.; Aigrot, M.S.; Trotter, M.; Huang, J.K.; Dauphinot, L.; Potier, M.C.; Kerninon, C.; Melik Parsadaniantz, S.; Franklin, R.J.M.; et al. Demyelination Causes Adult CNS Progenitors to Revert to an Immature State and Express Immune Cues That Support Their Migration. J. Neurosci. 2015, 35, 4–20. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Falcão, A.M.; van Bruggen, D.; Marques, S.; Meijer, M.; Jäkel, S.; Agirre, E.; Samudyata; Floriddia, E.M.; Vanichkina, D.P.; Ffrench-Constant, C.; et al. Disease-Specific Oligodendrocyte Lineage Cells Arise in Multiple Sclerosis. Nat. Med. 2018, 24, 1837–1844. [Google Scholar] [CrossRef] [PubMed]
- Zeis, T.; Enz, L.; Schaeren-Wiemers, N. The Immunomodulatory Oligodendrocyte. Brain Res. 2016, 1641, 139–148. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Birmpili, D.; Charmarke Askar, I.; Pham-Van, L.D.; Kuntzel, T.; Spenlé, C.; Riou, A.; Bagnard, D. Toward a Combination of Biomarkers for Molecular Characterization of Multiple Sclerosis. Int. J. Mol. Sci. 2022, 23, 14000. https://doi.org/10.3390/ijms232214000
Birmpili D, Charmarke Askar I, Pham-Van LD, Kuntzel T, Spenlé C, Riou A, Bagnard D. Toward a Combination of Biomarkers for Molecular Characterization of Multiple Sclerosis. International Journal of Molecular Sciences. 2022; 23(22):14000. https://doi.org/10.3390/ijms232214000
Chicago/Turabian StyleBirmpili, Dafni, Imane Charmarke Askar, Lucas Dinh Pham-Van, Thomas Kuntzel, Caroline Spenlé, Aurélien Riou, and Dominique Bagnard. 2022. "Toward a Combination of Biomarkers for Molecular Characterization of Multiple Sclerosis" International Journal of Molecular Sciences 23, no. 22: 14000. https://doi.org/10.3390/ijms232214000